Nautilus Biotechnology, Inc. - Form 8-K Summary
Business Context and Reporting Period
Nautilus Biotechnology, Inc. (Nasdaq: NAUT), an emerging growth company incorporated in Delaware, filed this Current Report on May 1, 2025. The filing addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the Company's compliance with listing standards.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The only financial metric disclosed is the stock price performance triggering the listing notice:
- Minimum Bid Price Requirement: $1.00 per share.
- Observed Performance: The closing bid price remained below $1.00 for 30 consecutive business days between March 19, 2025, and April 30, 2025.
Material Changes
The material change reported is the receipt of a formal notice from the Nasdaq Listing Qualifications Staff indicating a failure to satisfy the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1). This deficiency does not result in immediate delisting but initiates a formal compliance process.
Outlook, Risks, and Management Commentary
Compliance Period: The Company has been granted an initial 180-day compliance period ending October 28, 2025, to regain compliance.
Path to Compliance: To cure the deficiency, the stock must maintain a closing bid price of at least $1.00 for a minimum of ten consecutive business days during the compliance period.
Contingencies and Risks:
- If the Company fails to regain compliance by October 28, 2025, it may be eligible for a second 180-day compliance period by transferring to the Nasdaq Capital Market, subject to meeting other listing standards and paying an application fee.
- During a potential second compliance period, the Company may need to effect a reverse stock split to cure the deficiency.
- There is no assurance that the Company will be eligible for a second compliance period or that Nasdaq will grant continued listing if a delisting notification is issued.
Management Action: The Company intends to actively monitor its stock price and evaluate available options to resolve the deficiency.
Investor Verification Checklist
- Verify the current closing bid price of NAUT shares to assess proximity to the $1.00 threshold.
- Monitor the Company's stock price for ten consecutive business days to determine if the initial cure requirement is met.
- Review future filings for any announcements regarding a reverse stock split or application to transfer to the Nasdaq Capital Market.
- Check for any subsequent communications from Nasdaq regarding the status of the compliance period or potential delisting notices.